Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 6/20 | 0.60 |
| ▸ | NPBWR1 | P48145 | 11/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | CCKAR | P32238 | 1/20 | 0.54 |
| ▸ | CCKBR | P32239 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29748897 | 0.96 | GLP1R (0.61) | GLP1RNPBWR1RXFP1CCKARCCKBR | |
| SCHEMBL29669563 | 0.94 | GLP1R (0.62) | GLP1RNPBWR1RXFP1PCSK9 | |
| SCHEMBL13759835 | 0.94 | GLP1R (0.62) | GLP1RNPBWR1RXFP1PCSK9 | |
| SCHEMBL29555526 | 0.88 | NPBWR1 (0.64) | GLP1RNPBWR1CCKARCCKBROPRD1 | |
| SCHEMBL29555471 | 0.88 | NPBWR1 (0.64) | GLP1RNPBWR1CCKARCCKBROPRD1 | |
| SCHEMBL32660235 | 0.87 | GLP1R (0.61) | GLP1RRXFP1CCKARCCKBROPRD1 | |
| SCHEMBL30977971 | 0.87 | NPBWR1 (0.59) | NPBWR1 | |
| SCHEMBL31683247 | 0.87 | GLP1R (0.65) | GLP1RRXFP1CCKBRPCSK9 | |
| SCHEMBL3356603 | 0.87 | GLP1R (0.67) | GLP1RNPBWR1CCKBRPCSK9 | |
| SCHEMBL29475234 | 0.87 | GLP1R (0.62) | GLP1RRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137799-A1 | ANTI-MUC1* ANTIBODY DRUG COMPLEXES AND USES THEREOF | MINERVA BIOTECHNOLOGIES CORP (US) | 2026-05-21 | — | — | US | disclosed |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2025262181-A1 | METHOD TO IMPROVE THE PRODUCIBILITY OF A PEPTILIGASE ENZYME | Fresenius Kabi Ipsum S.R.L. (IT) | 2025-12-26 | — | — | WO | disclosed |
| EP-3600451-B1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12497644-B2 | Subtilisin variants and their use | Fresenius Kabi Ipsum S.R.L. (IT) | 2025-12-16 | — | — | US | disclosed |
| EP-4638730-A1 | THERMOSTABLE SUBTILISIN VARIANTS AND THEIR USE | Fresenius Kabi iPSUM S.r.l. (IT) | 2025-10-29 | — | — | EP | disclosed |
| US-12441847-B2 | Bi-functionalized polysiloxane brush copolymers | HENKEL AG & CO. KGAA (DE) | 2025-10-14 | — | — | US | disclosed |
| EP-3932973-B1 | BI-FUNCTIONALIZED POLYSILOXANE BRUSH COPOLYMERS | HENKEL AG & CO KGAA (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-20250255982-A1 | ANTI-MUC1* ANTIBODY DRUG COMPLEXES AND USES THEREOF | MINERVA BIOTECHNOLOGIES CORPORATION | 2025-08-14 | — | — | US | disclosed |
| EP-3628046-B1 | SUBTILISIN VARIANTS HAVING A MUTATION IN THE S2 OR S2' POCKET | FRESENIUS KABI IPSUM S R L (IT) | 2025-07-02 | — | — | EP | disclosed |
| US-20240043897-A1 | SUBTILISIN VARIANTS AND THEIR USE | Fresenius Kabi Ipsum S.R.L. (IT) | 2024-02-08 | — | — | US | disclosed |
| US-11879037-B2 | Preparation of polysiloxane polyalkyleneglycol brush copolymers | HENKEL AG & CO. KGAA (DE) | 2024-01-23 | — | — | US | disclosed |
| EP-4291647-A1 | SUBTILISIN VARIANTS AND THEIR USE | Fresenius Kabi iPSUM S.r.l. (IT) | 2023-12-20 | — | — | EP | disclosed |
| CN-117098843-A | Subtilisin variants and uses thereof | 费森尤斯卡比有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230117393-A1 | Bi-Functionalized Polysiloxane Brush Copolymers | LEIBNIZ-INSTITUT FUR KATALYSE E.V. (DE) | 2023-04-20 | — | — | US | disclosed |
| EP-3744758-B1 | ONIUM-FUNCTIONALIZED SILOXANES | HENKEL AG & CO KGAA (DE) | 2023-04-19 | — | — | EP | disclosed |
| US-11612572-B2 | Treatment of schizophrenia using beta-caryophyllene and CB2 receptor agonists | Ariel Scientific Innovations Ltd. (IL) | 2023-03-28 | — | — | US | disclosed |
| WO-2022171667-A1 | SUBTILISIN VARIANTS AND THEIR USE | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-08-18 | — | — | WO | disclosed |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-20220089820-A1 | Onium-Functionalized Siloxanes | HENKEL AG & CO. KGAA (DE) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117393-A1 | Bi-Functionalized Polysiloxane Brush Copolymers | SIGLEC7, SIGLEC9, PUF60 | GLP1R 4168/4885NPBWR1 576/4885RXFP1 4406/4885 |
| US-20220089820-A1 | Onium-Functionalized Siloxanes | ZYX, XDH, ITGA5 | GLP1R 1318/4885NPBWR1 3901/4885RXFP1 1200/4885 |
| US-12441847-B2 | Bi-functionalized polysiloxane brush copolymers | SIGLEC7, SIGLEC9, PUF60 | GLP1R 4168/4885NPBWR1 576/4885RXFP1 4406/4885 |
| US-20260137799-A1 | ANTI-MUC1* ANTIBODY DRUG COMPLEXES AND USES THEREOF | MUC1, IGLV6-57, CA14 | GLP1R 469/4885NPBWR1 2446/4885RXFP1 1283/4885 |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MCL1, POU2F1, NES | GLP1R 1811/4885NPBWR1 3584/4885RXFP1 857/4885 |
| US-20250255982-A1 | ANTI-MUC1* ANTIBODY DRUG COMPLEXES AND USES THEREOF | MUC1, EPCAM, CD44 | GLP1R 2330/4885NPBWR1 3350/4885RXFP1 3996/4885 |
| US-11612572-B2 | Treatment of schizophrenia using beta-caryophyllene and CB2 receptor agonists | CNR1, CNR2, CHRNE | GLP1R 819/4885NPBWR1 31/4885RXFP1 1609/4885 |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | GLP1R 3700/4885NPBWR1 4294/4885RXFP1 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.